ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F24%3A10486254" target="_blank" >RIV/00064165:_____/24:10486254 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/24:10486254

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=EO0CzYfwbJ" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=EO0CzYfwbJ</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1136/ijgc-2024-005823" target="_blank" >10.1136/ijgc-2024-005823</a>

Jazyk výsledku

angličtina

Název v původním jazyce

ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas

Popis výsledku v původním jazyce

A collaboration was established between the European Society of Gynaecological Oncology (ESGO), the European Reference Network on Rare Adult Solid Cancers (EURACAN), and the Gynecologic Cancer InterGroup (GCIG) with the aim of developing clinically relevant, evidence-based consensus guidelines on the management of patients with uterine sarcomas from diagnosis to relapse. ESGO/EURACAN/GCIG nominated practicing clinicians from centers of expertise in the management of patients with uterine sarcomas to serve on the expert panel (25 experts). To ensure that the statements were evidence-based, data identified from a systematic search were reviewed and critically appraised. In the absence of robust scientific evidence, clinical recommendations were based on the consensus of the international development group. Prior to publication, the guidelines were reviewed by 104 independent international clinicians with expertise in uterine sarcomas. Attention was given to imaging, pathology, and molecular analyses in addition to clinical management. Recommendations for surgery, including specific recommendations at initial diagnosis and at relapse, were developed. Indications for radiation and systemic therapies, including chemotherapy options, endocrine therapies, and targeted therapies, were addressed for the following histological subgroups of uterine sarcomas: high-grade endometrial stromal sarcomas, undifferentiated sarcomas, low-grade endometrial stromal sarcomas, uterine leiomyosarcomas, adenosarcomas, and selected very rare entities. Recommendations for follow-up and highlighted issues and unmet needs faced by long-term survivors were also discussed.

Název v anglickém jazyce

ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas

Popis výsledku anglicky

A collaboration was established between the European Society of Gynaecological Oncology (ESGO), the European Reference Network on Rare Adult Solid Cancers (EURACAN), and the Gynecologic Cancer InterGroup (GCIG) with the aim of developing clinically relevant, evidence-based consensus guidelines on the management of patients with uterine sarcomas from diagnosis to relapse. ESGO/EURACAN/GCIG nominated practicing clinicians from centers of expertise in the management of patients with uterine sarcomas to serve on the expert panel (25 experts). To ensure that the statements were evidence-based, data identified from a systematic search were reviewed and critically appraised. In the absence of robust scientific evidence, clinical recommendations were based on the consensus of the international development group. Prior to publication, the guidelines were reviewed by 104 independent international clinicians with expertise in uterine sarcomas. Attention was given to imaging, pathology, and molecular analyses in addition to clinical management. Recommendations for surgery, including specific recommendations at initial diagnosis and at relapse, were developed. Indications for radiation and systemic therapies, including chemotherapy options, endocrine therapies, and targeted therapies, were addressed for the following histological subgroups of uterine sarcomas: high-grade endometrial stromal sarcomas, undifferentiated sarcomas, low-grade endometrial stromal sarcomas, uterine leiomyosarcomas, adenosarcomas, and selected very rare entities. Recommendations for follow-up and highlighted issues and unmet needs faced by long-term survivors were also discussed.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30214 - Obstetrics and gynaecology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Gynecological Cancer

ISSN

1048-891X

e-ISSN

1525-1438

Svazek periodika

34

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

23

Strana od-do

1499-1521

Kód UT WoS článku

001320479700001

EID výsledku v databázi Scopus

2-s2.0-85206017175